Literature DB >> 6972248

Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin.

P P Trotta, A Tedde, S Ikehara, R Pahwa, R A Good, M E Balis.   

Abstract

The effect of continuous infusion into C57BL/6J mice of 2'-deoxycoformycin (DCF), a tight-binding inhibitor of adenosine deaminase, on the biological function of bone marrow stem cells and T- and B-lymphocytes was evaluated. Greater than 85% inhibition of adenosine deaminase in erythrocytes, thymus, and bone marrow was noted after DCF infusion at 0.4 mg per kg body weight per day, while lesser extents of inhibition were characteristic of spleen and lymph nodes. The reconstitution of lethally irradiated C57BL/6J mice with bone marrow cells from DCF- and 0.9% NaCl infused mice of the same strain was compared. The two groups of animals were virtually identical with respect to (a) the number of spleen colony-forming units, (b) the response of splenic lymphocytes to both B- and T-cell mitogens, (c) hematological analysis of peripheral blood elements, and (d) survival time, thus strongly supporting the lack of effect of DCF infusion on the capacity of stem cells to differentiate. In contradistinction, DCF infusion was highly lymphocytotoxic as noted by the severe necrosis in both B- and T-cell regions in lymph nodes and spleen and by the dramatic weight reduction in spleen and thymus. Histopathology of other tissues including bone marrow was normal except for the occurrence of hepatitis. A striking decrease in blastogenesis induced by the mitogens concanavalin A, phytohemagglutinin, and Escherichia coli lipopolysaccharides was also observed after DCF infusion. Consistent with these data, in vitro incubation of bone marrow cells with DCF did not impair the number of spleen colony-forming units produced in lethally irradiated mice. These data suggest a potential use for adenosine deaminase inhibitors in the prevention of graft-versus-host disease in hematopoietic transplantation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6972248

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.

Authors:  R F Kefford; R M Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

2.  The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.

Authors:  Jacopo Mariotti; Justin Taylor; Paul R Massey; Kaitlyn Ryan; Jason Foley; Nicole Buxhoeveden; Tania C Felizardo; Shoba Amarnath; Miriam E Mossoba; Daniel H Fowler
Journal:  Biol Blood Marrow Transplant       Date:  2010-12-03       Impact factor: 5.742

3.  Immunomorphological localization of adenosine deaminase in rat tissues during ontogeny.

Authors:  B E Chechik; S Sengupta; T Hibi; B Fernandes
Journal:  Histochem J       Date:  1985-02

Review 4.  Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.